Our weekly market outlook, straight to your inbox.

Get the Schaeffer’s edge every Monday.

 

 
 
 
X

Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

Nov 3, 2015, 09:29 AM by Andrea Kramer
Today's stocks to watch include Mobileye NV (MBLY), Activision Blizzard, Inc. (ATVI), and Aquinox Pharmaceuticals Inc (AQXP)
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.

Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.

Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.
  

ABOUTus


Schaeffer's Investment Research, Inc. has been providing stock market publications, market recommendation services and stock option education since its inception in 1981 by founder and CEO, Bernie Schaeffer.  Headquartered in Cincinnati, OH, Schaeffer's Investment Research has become a leading and trusted source of research and analysis for individual investors and major financial media outlets.

TRADINGpublications


|FROM THE TOP
by bernie schaeffer
Because today's investor is aware of the benefits of options trading, options investing is shifting to mainstream popularity, Bernie Schaeffer, author of The Option Advisor, continues to provide accessible, sophisticated analysis and research of options trading for every investor in his weekly and monthly columns.

Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.
From The Top

Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.
|MONDAY MORNING OUTLOOK
by todd salamone
Todd Salamone is the Senior VP of Research and author of the Monday Morning Outlook. To receive your weekly column, subscribe to Monday Morning Outlook.

Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.
|INDICATOR OF THE WEEK
by rocky white
Rocky White is a quantitative analyst at Schaeffer’s Research and author of Indicator of the Week. To get more tips on options indicators, subscribe to any of our free publications.

Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.
Weekly Publications

Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.

TRADING SERVICES | FEATUREDproducts


By E.W. from Kentucky
I have tried many different programs and services in the past with mix results. Stop your search here. Schaeffer's Investment Research is bottom line the most professional, experienced, and confidence building investment research firm. After trying an initial package I spoke with my account manager, Nathane Sharp, who helped me tailor my trading style to the right package. His professionalism and experienced approach matched me perfectly. The track record speaks for itself and the money back guarantee sells you. I have found my investment firm for the rest of my trading career.
Options trading made simple.
Schaeffer's Investment Research, Inc. is dedicated to providing subscribers advantages in options trading and investing.  Our independent market research services create profitable opportunities for investors at every level.
FREE NEWS & ALERTS

Get the best of Schaeffer's financial market news every morning directly to your inbox.

Find Out How

TRENDINGnews


Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.

OPTIONSnews


Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.

EDITOR'Spicks


Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.

ANALYSTupdates


Buzz Stocks: Mobileye NV, Activision Blizzard, Inc., and Aquinox Pharmaceuticals Inc

by Andrea Kramer | Nov 03, 2015
U.S. stocks are set to take a breather after Monday's surge. Among the equities in focus are driver-assistance software concern Mobileye NV (NYSE:MBLY), video game maker Activision Blizzard, Inc. (NASDAQ:ATVI), and biotech Aquinox Pharmaceuticals Inc (NASDAQ:AQXP).

  • MBLY is pointed 3% higher ahead of the bell, after the firm reported stronger-than-expected third-quarter earnings and sales. What's more, a short squeeze could add fuel to the shares' fire. Short interest accounts for nearly 20% of Mobileye NV 's total available float, representing 11 sessions' worth of pent-up buying demand, at the stock's average pace of trading. However, will it be enough to boost MBLY above its 10-week moving average? This trendline -- currently docked at $47.63 -- has stifled MBLY's rebound attempts since the August swoon. On Monday, MBLY settled at $45.54.
  • ATVI is fractionally lower in pre-market trading, as traders digest the "Call of Duty" producer's third-quarter earnings and plans to buy "Candy Crush" maker King Digital Entertainment PLC (NYSE:KING) for $5.9 billion. Heading into earnings, Activision Blizzard, Inc. was surrounded by pessimism. It would take about seven sessions to repurchase all the shorted ATVI shares, at the equity's average pace of trading, and the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.59 stands higher than 84% of all other readings from the past year. In other words, near-term options traders have rarely been more put-biased. Still, ATVI has already shaken off most of its post-earnings losses. Should the stock turn higher, a mass exodus of bears could help ATVI extend its year-to-date lead of more than 71.5%. Yesterday, ATVI finished at $34.57 -- within a point of record-high territory.
  • AQXP is poised for a 10% plunge out of the gate, after the firm's experimental skin drug failed a mid-stage study. Aquinox Pharmaceuticals Inc said it will now focus on further development of AQX-1125, its experimental bladder drug that caused much fanfare last month, and said it's looking forward to its Dec. 8 meeting with the Food and Drug Administration (FDA) about "pivotal trial designs." On the charts, AQXP has been stagnating in the $15-$20 range for the past few weeks, closing at $16.36 yesterday. Should the stock take a turn for the worse and breach the lower end of this rail, it could be vulnerable to downgrades. Currently, five out of six analysts offer up "buy" or better opinions.

Partnercenter


OURfans